510(k) Report

510(k) · Cleared

Cleared

Nofact IX

K102908510(k) TraditionalCleared Dec 19, 2011444-day reviewClass II21 CFR 864.7290

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

R2 Diagnostics, Inc. · GJT Plasma, Coagulation Factor Deficient

Cleared on Dec 19, 2011 as substantially equivalent to K933432 (American Bioproducts Co., 1993) after a 444-day review. Its family tree reaches back 1 generation to 1993.

Decided
Dec 19, 2011
Review
444 days
Class
Class II
Product code
GJT
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to K933432 (1993). No later device cites it as a predicate yet.

K933432 · Stago Factor IX-Deficient Plasma · American Bioproducts Co. · 199319901995200020052010
  1. Root · 1 generation backK933432 Stago Factor IX-Deficient PlasmaAmerican Bioproducts Co. · 1993
  2. This deviceK102908 Nofact IXR2 Diagnostics, Inc. · 2011
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K933432Stago Factor IX-Deficient PlasmaAmerican Bioproducts Co.1993—
0 (this device)K102908Nofact IXR2 Diagnostics, Inc.2011—
FIG. 1 — Lineage of K102908, 1993–2011Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in GJT? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new GJT device

  1. #1 K222831 CRYOcheck Factor VIII Deficient Plasma with VWFscore 6.6 · 3 generations · no Class I recall
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K933432Stago Factor IX-Deficient Plasma
Summary page 1
…e Name: NoFact IX Classification Name: Plasma, Factor Deficient (21CFR 864.7290, Product Code GJT) 3) Predicate Device(s) Stago IX Deficient Plasma (K(933432) 4) Device Description(s) NoFact IX Deficient Plasma is a human plasma inmmodepleted of Factor IX and intended for the quantita…
American Bioproducts Co.1993—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.

How does its category compare?

All GJT devices

GJT Plasma, Coagulation Factor Deficient: FDA decisions, review times, recalls and adverse event reports over 20 years. 2011, this device’s year, is highlighted.

FDA decisions per year · GJT

1in 2023

2011: 32018: 12023: 1
2007high 3 (2011) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · GJT

444in 2011

2011: 444 days median
2007high 444 (2011)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · GJT

1in 2013

2013: 1
2007high 1 (2013) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · GJT

1in 2025

2013: 32017: 12018: 62020: 12024: 22025: 1
2007high 6 (2018) · low 0 (2007)2025

MAUDE reports naming product code GJT, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
2011344400
20120—00
20130—13
20140—00
20150—00
20160—00
20170—01
20181—06
20190—00
20200—01
20210—00
20220—00
20231—00
20240—02
20250—01
20260—0—

What is it indicated for?

NoFact IXDeficient Plasma is a human plasma immunodepleted of Factor IXand intended for the quantitative determination of Factor IX activity in citrated plasma from patients suspected of FIX deficiency. FIX activity is based on the activated partial thromboplastin time. For in vitro diagnostic use.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K102908: Nofact IX.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K102908

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026